San Diego-based Ambrx appointed Lawson Macartney, Ph.D., D.V.M., to president and CEO and a member of the board of directors, the company announced Monday.
Macartney brings more than 20 years of experience in the pharmaceutical industry, including recent work growing and diversifying the clinical pipeline of Shire Pharmaceuticals as senior vice president and head of emerging business unit.
Prior to joining Shire in 2011, Macartney was senior vice president of global product strategy and project/portfolio management for GlaxoSmithKline PLC. In this role, he spent four years overseeing the commercial evaluation and commercial strategy for assets at all stages of development and identifying in-licensing opportunities. He previously held additional positions at GlaxoSmithKline, Astra Pharmaceuticals and Ribozyme Pharmaceuticals.
Macartney received his doctorate from Glasgow University and a veterinary doctorate from Glasgow University Veterinary School. He is a member of the Royal College of Veterinary Surgeons and a fellow of the Royal College of Pathologists.